{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:16:58Z","timestamp":1792163818670,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T00:00:00Z","timestamp":1301011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00213-011-2256-x","type":"journal-article","created":{"date-parts":[[2011,3,24]],"date-time":"2011-03-24T01:06:13Z","timestamp":1300928773000},"page":"579-587","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia"],"prefix":"10.1007","volume":"216","author":[{"given":"Tom","family":"Stargardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Mavrogiorgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Gericke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Juckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,25]]},"reference":[{"key":"2256_CR1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1192\/bjp.184.4.346","volume":"184","author":"S Almond","year":"2004","unstructured":"Almond S, Knapp M, Francois C et al (2004) Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184:346\u2013351","journal-title":"Br J Psychiatry"},{"key":"2256_CR2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0278-5846(92)90024-9","volume":"16","author":"G Budde","year":"1992","unstructured":"Budde G (1992) Efficacy and tolerability of flupenthixol decanoate in the treatment of depression and psychosomatic disorders: a multicenter trial in general practice. Prog Neuropsychopharmacol Biol Psychiatr 16:677\u2013689","journal-title":"Prog Neuropsychopharmacol Biol Psychiatr"},{"key":"2256_CR3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1176\/ajp.156.6.863","volume":"156","author":"RR Conley","year":"1999","unstructured":"Conley RR, Love RC, Kelly DL et al (1999) Rehospitalisation rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 156:863\u2013868","journal-title":"Am J Psychiatry"},{"key":"2256_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10401230309085667","volume":"15","author":"RR Conley","year":"2003","unstructured":"Conley RR, Kelly DL, Love RC et al (2003) Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 15:23\u201331","journal-title":"Ann Clin Psychiatry"},{"key":"2256_CR5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.109.066217","volume":"196","author":"NA Crossley","year":"2010","unstructured":"Crossley NA, Constante M, McGuire P, Power P (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196:434\u2013439","journal-title":"Br J Psychiatry"},{"key":"2256_CR6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","volume":"346","author":"JG Csernansky","year":"2002","unstructured":"Csernansky JG, Mahmoud R, Brenner R (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16\u201322","journal-title":"N Engl J Med"},{"key":"2256_CR7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","volume":"60","author":"J Davis","year":"2003","unstructured":"Davis J, Chen N, Glick I (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553\u2013564","journal-title":"Arch Gen Psychiatry"},{"key":"2256_CR8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0447.1986.tb06242.x","volume":"74","author":"G Eberhard","year":"1986","unstructured":"Eberhard G, Hellbom E (1986) Haloperidol decanoate and flupentixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Acta Psychiatr Scand 74:255\u2013262","journal-title":"Acta Psychiatr Scand"},{"key":"2256_CR9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1055\/s-2004-832684","volume":"37","author":"WF Gattaz","year":"2004","unstructured":"Gattaz WF, Diehl A, Geuppert MS et al (2004) Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 37:279\u2013285","journal-title":"Pharmacopsychiatry"},{"key":"2256_CR10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","volume":"321","author":"J Geddes","year":"2000","unstructured":"Geddes J, Freemantle N, Harrison P et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371\u20131376","journal-title":"BMJ"},{"key":"2256_CR11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/j.1875-9114.1991.tb02660.x","volume":"11","author":"AJ Gruber","year":"1991","unstructured":"Gruber AJ, Cole JO (1991) Antidepressant effects of flupenthixol. Pharmacotherapy 11:450\u2013459","journal-title":"Pharmacotherapy"},{"key":"2256_CR12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1600-0447.107.s416.4.x","volume":"107","author":"JM Haro","year":"2003","unstructured":"Haro JM, Edgell ET, Frewer P et al (2003) The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings across country and treatment. Acta Psychiatr Scand 107:7\u201315","journal-title":"Acta Psychiatr Scand"},{"key":"2256_CR13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000068874","volume":"47","author":"I Hertling","year":"2003","unstructured":"Hertling I, Philipp M, Dvorak A et al (2003) Flupentixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 47:37\u201346","journal-title":"Neuropsychobiology"},{"key":"2256_CR14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","volume":"63","author":"PB Jones","year":"2006","unstructured":"Jones PB, Barnes TR, Davies L et al (2006) Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079\u20131087","journal-title":"Arch Gen Psychiatry"},{"key":"2256_CR15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2004-813027","volume":"66","author":"R Kilian","year":"2004","unstructured":"Kilian R, Angermeyer MC, Becker T (2004) Methodische Grundlagen naturalistischer Beobachtungsstudien zur \u00f6konomischen evaluation der Neuroleptikabehandlung bei schizophrenen Erkrankungen. Gesundheitswesen 66:180\u2013185","journal-title":"Gesundheitswesen"},{"key":"2256_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2007-993735","volume":"67","author":"W Kissling","year":"1999","unstructured":"Kissling W, H\u00f6ffler J, Seemann U et al (1999) Direct and indirect costs of schizophrenia. Fortschr Neurol Psychiatr 67:29\u201336","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2256_CR17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0447.1985.tb08540.x","volume":"322","author":"P Knudsen","year":"1985","unstructured":"Knudsen P (1985) Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand 322:51\u201375","journal-title":"Acta Psychiatr Scand"},{"key":"2256_CR18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0028-1090234","volume":"36","author":"A Konnopka","year":"2009","unstructured":"Konnopka A, Klingberg S, Wittorf A, K\u00f6nig HH (2009) The cost of schizophrenia in Germany: a systematic review of the literature. Psychiat Prax 36:211\u2013218","journal-title":"Psychiat Prax"},{"key":"2256_CR19","first-page":"38","volume":"68","author":"KU K\u00fchn","year":"2000","unstructured":"K\u00fchn KU, Meyer K, Maier W (2000) Flupentixol-a partial atypical neuroleptic. Fortschr Neurol Psychiatr 68:38\u201341","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2256_CR20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"2256_CR21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1176\/ajp.154.3.337","volume":"154","author":"JS Lyons","year":"1997","unstructured":"Lyons JS, O'Mahoney MT, Miller SI et al (1997) Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Am J Psychiatry 154:337\u2013340","journal-title":"Am J Psychiatry"},{"key":"2256_CR22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/PL00014191","volume":"24","author":"HJ M\u00f6ller","year":"1999","unstructured":"M\u00f6ller HJ (1999) Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatr Clin Neurol sci 24:99\u2013107","journal-title":"Eur Arch Psychiatr Clin Neurol sci"},{"key":"2256_CR23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-2002-34655","volume":"29","author":"P M\u00fcller","year":"2002","unstructured":"M\u00fcller P, Nerenz H, Schaefer E (2002) The risk of rehospitalisation during therapy with atypical and typical neuroleptics\u2014a contribution to differential indication. Psychiatr Prax 29:388\u2013391","journal-title":"Psychiatr Prax"},{"key":"2256_CR24","first-page":"161","volume":"5","author":"J Pach","year":"1998b","unstructured":"Pach J, Bertling R, Finkbeiner T et al (1998a) Rezidive bei schizophrenen Erkrankungen unter Depot-Neuroleptika. Ergebnisse einer 1-j\u00e4hrigen Doppelblindstudie mit Flupentixol-Decanoat. Psychopharmakotherapie 5:161\u2013165","journal-title":"Psychopharmakotherapie"},{"key":"2256_CR25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-2007-995283","volume":"66","author":"J Pach","year":"1998a","unstructured":"Pach J, Finkbeiner T, Glaser T et al (1998b) Positiv- und Negativsymptomatik bei chronisch schizophrenen Patienten unter Erhaltungstherapie mit Flupentixoldecanoat im 12-Monatsverlauf. Fortschr Neurol Psychiatr 66:442\u2013449","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2256_CR26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1055\/s-2003-39746","volume":"30","author":"M Philipp","year":"2003","unstructured":"Philipp M, Lesch OM, Schmauss M et al (2003) Comparative effectiveness of flupentixol and risperidone on negative symptoms of schizophrenia. Psychiatr Prax 30:94\u201396","journal-title":"Psychiatr Prax"},{"key":"2256_CR27","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","volume":"290","author":"R Rosenheck","year":"2003","unstructured":"Rosenheck R, Perlick D, Bingham S et al (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693\u20132702","journal-title":"JAMA"},{"key":"2256_CR28","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","volume":"2","author":"S Saha","year":"2005","unstructured":"Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141","journal-title":"PLoS Med"},{"key":"2256_CR29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1176\/appi.ajp.160.2.310","volume":"160","author":"MJ Sernyak","year":"2003","unstructured":"Sernyak MJ, Leslie D, Rosenheck R (2003) Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 160:310\u2013315","journal-title":"Am J Psychiatry"},{"key":"2256_CR30","first-page":"89","volume":"11","author":"T Stargardt","year":"2008","unstructured":"Stargardt T, Weinbrenner S, Busse R et al (2008) Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ 11:89\u201397","journal-title":"J Ment Health Policy Econ"},{"key":"2256_CR31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1176\/appi.ps.54.4.508","volume":"54","author":"P Thieda","year":"2003","unstructured":"Thieda P, Beard S, Richter A et al (2003) An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 54:508\u2013516","journal-title":"Psychiatr Serv"},{"key":"2256_CR32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.38881.382755.2F","volume":"333","author":"J Tiihonen","year":"2006","unstructured":"Tiihonen J, Wahlbeck K, L\u00f6nnqvist J et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333:224","journal-title":"BMJ"},{"key":"2256_CR33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","volume":"154","author":"GD Tollefson","year":"1997","unstructured":"Tollefson GD, Beasley CM, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457\u2013465","journal-title":"Am J Psychiatry"},{"key":"2256_CR34","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","volume":"156","author":"K Wahlbeck","year":"1999","unstructured":"Wahlbeck K, Cheine M, Essali A et al (1999) Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 156:990\u2013999","journal-title":"Am J Psychiatry"},{"key":"2256_CR35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/schbul\/21.3.419","volume":"21","author":"PJ Weiden","year":"1995","unstructured":"Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21:419\u2013429","journal-title":"Schizophr Bull"},{"key":"2256_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2007-993224","volume":"41","author":"S Weinbrenner","year":"2008","unstructured":"Weinbrenner S, Assion HJ, Stargardt T et al (2008) Drug prescription patterns in schizophrenia outpatients: analysis of data from German health insurance fund. Pharmacopsychiatry 41:1\u20136","journal-title":"Pharmacopsychiatry"},{"key":"2256_CR37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.schres.2003.11.005","volume":"71","author":"PL Zhang","year":"2004","unstructured":"Zhang PL, Santos JM, Newcomer J et al (2004) Impact of atypical antipsychotics on quality of life, selfreport of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res 71:137\u2013144","journal-title":"Schizophr Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2256-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-011-2256-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2256-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T11:10:19Z","timestamp":1712315419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-011-2256-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,25]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["2256"],"URL":"https:\/\/doi.org\/10.1007\/s00213-011-2256-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,25]]}}}